ReviewNature reviews. Gastroenterology & hepatology2013
Future therapies for chronic hepatitis C.
Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.Antimicrobial agents and chemotherapy · 2014Trial
- Article
- Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.PloS one · 2017Article
- Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion.Experimental and therapeutic medicine · 2016Article
- Therapeutic Potential of Spirooxindoles as Antiviral Agents.ACS infectious diseases · 2016Review
- Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.The Journal of general virology · 2016Article
- Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans.Journal of clinical and translational hepatology · 2015Article
- Article
- Current strategies for quantitating fibrosis in liver biopsy.Chinese medical journal · 2015Review
- Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication.International journal of nanomedicine · 2015Article
- One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.BioMed research international · 2015Article
- Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease.Acta pharmacologica Sinica · 2014Article
- The acyclic retinoid Peretinoin inhibits hepatitis C virus replication and infectious virus release in vitro.Scientific reports · 2014Article
- HCV transmission in industrialized countries and resource-constrained areas.Nature reviews. Gastroenterology & hepatology · 2014Review
- Chemopreventive strategies in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2014Review
- Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment.TheScientificWorldJournal · 2014Review
- Emerging concepts in immunity to hepatitis C virus infection.The Journal of clinical investigation · 2013Review
- Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.Nature medicine · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy for hepatitis C has been fairly stagnant for the past decade, but the past few years have seen major progress and evolution, beginning with the approval of two HCV protease inhibitors in 2011. In spite of considerable improvements in response rates with these agents, a need for additional agents with improved potency and tolerability remains. Toward this goal and over the course of just a few months, the HCV therapy pipeline has already become crowded with direct-acting antivirals, host-targeted agents and unique interferons, all of which are positioned to be part of the next wave of therapeutic options. The ultimate goal of this push for new agents is to achieve a safe and straight forward yet highly effective therapy for hepatitis C that is widely embraced and readily available. Particularly among the 'baby boomer' population, it is predicted that over the next few years, more patients with currently quiescent infections will be newly diagnosed, and those currently diagnosed will be at increased risk of long-term complications of infection, and thus in need of treatment. A simple and safe treatment paradigm will become a necessity. This Review chronicles the latest developments in hepatitis C therapy and the potential effect these new treatments could have on delivery of care to patients infected with HCV.
Indexed as
Identifiers
23419289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.